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Background: The in vivo transfer of naked plasmid DNA into organs such as muscles is commonly used to assess
the expression of prophylactic or therapeutic genes in animal disease models.
Results: In this study, we devised vectors allowing a tight regulation of transgene expression in mice from such
non-viral vectors using a doxycycline-controlled network of activator and repressor proteins. Using these vectors,
we demonstrate proper physiological response as consequence of the induced expression of two therapeutically
relevant proteins, namely erythropoietin and utrophin. Kinetic studies showed that the induction of transgene
expression was only transient, unless epigenetic regulatory elements termed Matrix Attachment Regions, or MAR,
were inserted upstream of the regulated promoters. Using episomal plasmid rescue and quantitative PCR assays, we
observed that similar amounts of plasmids remained in muscles after electrotransfer with or without MAR elements,
but that a significant portion had integrated into the muscle fiber chromosomes. Interestingly, the MAR elements
were found to promote plasmid genomic integration but to oppose silencing effects in vivo, thereby mediating
long-term expression.
Conclusions: This study thus elucidates some of the determinants of transient or sustained expression from the
use of non-viral regulated vectors in vivo.
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Progress has been made on therapeutic gene regulation
systems applicable to gene therapies, in which transgene
expression is controlled pharmacologically by administer-
ing a small molecule drug. One of the favorite systems is
based on the bacterial tetracycline-repressed TetR protein
of E. coli [1,2]. It relies on inducer compounds with a
proven history of medical safety, i.e. tetracycline and deriv-
atives, which regulate the ability of engineered TetR pro-
tein derivatives to bind particular DNA sequences inserted
in target promoters. With this system, regulation of the
mouse erythropoietin gene has been achieved in mice
muscles over periods of several months using non-viral
or viral vectors. For instance, beta-thalassemic mice
were rendered steadily normocythemic by intramuscular* Correspondence: nicolas.mermod@unil.ch
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reproduction in any medium, provided the orinjection of a tetracycline-inducible AAV vector encoding
mouse erythropoietin (EPO), and doxycycline dosage
was used to control hematocrit [2]. No adverse immune
response against the bacterial protein was noted. How-
ever “leaky” expression in absence of the tetracycline
derivative was often noted, especially at high transgene
copy numbers [3,4].
To alleviate this problem, several improved versions
have been developed, whereby activators and repressors
of gene expression are combined [5-8]. These new ver-
sions display little or no basal activity, while they main-
tain induced expression at levels sufficient to achieve
physiological effects in rodents. One of the tightest gen-
etic switch systems for controlled transgene transcrip-
tion relies on chimerical repressor and activator proteins
functioning in a regulatory network [6,9]. The hallmark
of this system is the efficient transgene silencing in the
OFF-state, while addition of the inducer drug allowed
for robust activation of transgene expression in vitro and
in vivo [10].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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achieved for periods up to one year in normal C57Bl6
mice, without detectable immune response [11], although
induced expression has occasionally been found to decline
with time in vivo. Gene regulation was also achieved with
these vectors after DNA transfer in non-human primates,
but with a reduced regulatory window as compared to
mice. Another limitation observed in long-term experi-
ments has been the potential immunogenicity of some of
the Tet-derived proteins in monkeys, which can also hin-
der long term expression regulation [11-13].
In addition to improvements of the DNA vector ele-
ments, gene delivery strategies have also been under intense
scrutiny over the past years with regard to therapeutic gene
transfer, with viral vectors being most prominent. For in-
stance, retroviral or lentiviral vectors have been used widely
as they mediate efficient transduction into the cell nucleus
and transgene integration into the cell genome. However,
such viral vectors often integrate preferentially into or near
cellular genes, which has caused adverse effects in clinical
trials [14]. As of yet, such tropism has not been reported
for non-viral vectors. Thus, non-viral gene transfer is also
currently considered as an alternative, especially with non-
integrating vectors or with vectors that do not integrate
preferentially into genes [15].
Recombinant AAV vectors can efficiently transduce
muscles after systemic administration in normal mice
[16], and AAV vectors carrying a microdystrophin gene
were shown to correct the phenotype of dystrophic mdx
mice [17]. However, the AAV capsid cannot accommo-
date a cargo size like full-length utrophin or dystrophin
cDNA, and novel AAV vectors were thus developed to
increase the transgene capacity by trans-splicing [18].
This system takes advantage of AAV’s ability to form
head-to-tail concatemers by the recombination of the
ITRs. In this approach, the transgene cassette is split be-
tween two rAAV vectors containing adequately placed
splice donor and acceptor sites. Transcription from two
rAAV vectors followed by correct trans-splicing of the
mRNA transcripts can results in a functional gene prod-
uct. This application can be used to deliver therapeutic
genes up to 9 kb in size, which is not sufficient to confer
full-length dystrophin or utrophin expression.
Non-viral vectors like plasmids can accommodate cod-
ing sequences such as that of full-length dystrophin, as
can be required to fully correct human dystrophy, but they
are subject to a lower efficiency of DNA transfer. One of
the most efficient physical DNA transfer methods in vivo
consists of the electrotransfer approach, which is also re-
ferred to as in vivo electroporation [19]. DNA is injected
into an organ or tissue of choice, and an electrical field is
applied to promote or increase the entry of the DNA into
the cells. Although systemic intramuscular treatment is
not feasible, localized electroporation has often been usedto achieve transient or more persistent expression of genes
of interest in animal disease models, and it has also been
used in humans, in clinical trials [19,20].
The purpose of this study was to achieve and docu-
ment tight transgene expression regulation in an animal
model of muscle diseases using non-viral vectors. We re-
port that sustained transgene regulation requires matrix
attachment regions (MAR) epigenetic regulatory se-
quences, and we show that these elements not only favor
stable and long-term expression but that they also pro-
mote the chromosomal integration of the transgenes
in vivo.
Results
Establishment of optimal conditions for in vivo transgene
control in mice muscles
The regulatory network system used in this study con-
sists of a constitutively expressed TetR-based transcrip-
tional repressor that inhibits the expression of both an
activator gene and of the gene of interest in the absence
of doxycycline. Addition of doxycycline inactivates the
repressor, relieving the expression of the transcriptional
activator, which will in turn activate its own expression
in a positive feed-back loop, and as well as that of a
therapeutic or reporter gene (Figure 1A). Previous work
has shown that this system can yield tight transgene ex-
pression regulation in stable cell lines in culture [6,9].
The efficiency of this regulatory network in vivo was
quantified first using a reporter gene encoding luciferase.
Plasmids encoding the 3 components of the network (i.e.
the repressor, activator and reporter) were electrotrans-
ferred in the tibial cranial muscles of C57Bl/6 mice, and
luciferase activity was assayed from muscle extracts. Ini-
tial assays using the network components, as previously
characterized and optimized in cultured cells, yielded a
relatively smaller regulatory window in vivo (data not
shown). Thus, we set up to improve the performance of
this network for in vivo use, as described below.
One of the improvements involved the identification of
a more potent repressor protein, coupled to a constitu-
tive promoter that was not subjected to silencing effects
in vivo and that had a suitable strength. Various repressor
constructs were generated from previously characterized
potent transcriptional repression domains, such as the
hormone-insensitive truncated version of the hormone-
binding domain of the thyroid hormone receptor fused to
the hairy protein tetrapeptide WRPW (TR450W, [9]). Al-
ternatively, we used the KRAB repressor domains of Kox1
[21] of Even-skipped (koxeve) [22], or a fusion of the
WRPW tetrapeptide and of the SID domain of human
hMad (koxW) [23]. Expression of these repressors from
the cellular β actin promoter and co-transfer with the 2
other components of the network yielded comparable ex-
pression levels upon the addition of doxycycline to the
Figure 1 Construction of a gene network for regulated transgene expression in vivo. (A) The regulatory network-based expression system
assessed in this study consists of 3 plasmid components encoding a constitutively expressed repressor, an inducible activator, and a reporter or
therapeutic gene regulated by both the repressor and the activator proteins. Without doxycycline, the repressor protein binds to and represses
the promoters of the two other plasmids. Doxycycline binds to and inactivates the repressor, which relieves the activator promoter from
repression and allows low expression levels to establish. As the activator is expressed, it activates it own expression as well as that of the reporter
gene, gradually increasing expression to maximally induced levels. (B) The strength of various repressor constructs was evaluated by the
electrotransfer of the network’s three plasmid components into the tibialis anterior muscle of wild type mice, using the luciferase coding
sequence as a reporter gene. Mice were provided doxycycline (+ dox) or not (− dox) in the drinking water and they were sacrificed after two
weeks. The relative luciferase activity was determined from muscle extracts. Numbers indicate the fold-induction of normalized luciferase activities
by doxycycline. (C) The strength of the prokaryotic part of the chimeric TetR-TR450W repressor was compared when expressing the fusion protein
either from the bacterial DNA sequence of from a DNA sequence with “humanized” codons [24]. (D) Performance of the network system
controlled by the humanized TetR (hTetR) fused to the TR450W repressor domain expressed from the β actin promoter in mice muscles, as a
comparison to that obtained from the original pTet-ON™ system (Clontech) electrotransferred similarly. Fold activations obtained upon the addition of
doxycyclin are as indicated above each filled bar. Each column represents the mean of values obtained from 16 muscles of 8 mice per condition.
Puttini et al. BMC Molecular Biology 2013, 14:26 Page 3 of 12
http://www.biomedcentral.com/1471-2199/14/26drinking water of mice (Figure 1B). However, without
doxycycline, the TR450W repressor provided a more
tightly repressed expression in the OFF state.
We also compared the strength of the KoxW repressor
domain fused either to the original bacterial TetR se-
quence or to a version engineered to contain a human-
ized coding sequence, for more efficient expression in
mammalian organisms (hTetR) [24]. As expected, there
was no difference when comparing the transgene expres-
sion levels as induced by the presence of doxycycline,
when the two repressors are in an inactive state. How-
ever, in the absence of doxycyclin, the humanized TetR
version conferred a 10-fold tighter repression of the
regulatory system (Figure 1C). When expressed from thechicken β-actin promoter, the fusion of the humanized
hTETR moiety to the TR450W repressor domain pro-
vided a dose dependent repression of expression that
proved superior to that mediated by alternative repres-
sors (Additional file 1 and data not shown). When com-
bining all these improvements, the regulatory network
provided high induced expression without compromis-
ing tightness, yielding a 1’500-fold regulatory window in
muscles in vivo (Figure 1D).
Regulated expression of a therapeutic transgene in
mouse muscles
We next assessed whether the regulatory network may
mediate expression at levels sufficiently high to mediate
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phin is a protein homologous to dystrophin, the protein
missing in Duchenne muscular dystrophy (DMD) pa-
tients. High-level expression of the fetal utrophin protein
was shown to substitute dystrophin and to yield sus-
tained muscle function without a potential immune re-
sponse in the mdx mouse model of DMD that lacks
dystrophin [25]. The large size of the utrophin or dys-
trophin coding sequences exceeds the capacity of viral
vectors, and although certain high capacity adenoviral
vectors could circumvent this limitation, these vectors
are still hampered by immunogenicity and gene transfer
problems in adult muscles [26]. Therefore, current clin-
ically relevant viral vectors are only able to accommo-
date truncated forms of these therapeutic proteins, with
the perspective to convert Duchenne muscular dys-
trophy into relatively milder Becker dystrophies [27].
However, non-viral plasmid DNA vectors are not sub-
jected to similar limitations, and this approach was shown
to yield up to 50% of the muscle fibers expressing a GFP
transgene, which should be sufficient to achieve a thera-
peutically effective treatment of skeletal muscles [28,29].
Thus, expression of utrophin from the regulatory network
was evaluated after in vivo electrotransfer of the tibialis
anterior muscles of dystrophic mdx mice. As previously
reported, utrophin cDNA transfer can elevate utrophin
protein levels to about 2-fold with the current electropor-
ation protocol [29]. Here, the therapeutic efficacy of
utrophin expression from the regulatory network was
evaluated by Atomic Force Microscopy (AFM), as it was
previously shown to provide a sensitive approach to reveal
the recovery of normal muscle resistance and strength
upon utrophin or dystrophin expression from the assay of
single muscle fibers [29]. Fifteen days after electrotransfer
and doxycycline induction, some of the mdx muscle fibers
were found to be more resistant to elastic deformation
than untreated mdx fibers, yielding Young’s Modulus
elasticity values in the 2 to 6 kPa range typical of healthy
murine muscles (Figure 2A and D). Modeling of the distri-
bution of the Young’s Modulus values of individual muscle
fibers indicated that approximately 50% of the fibers had
increased mechanical resistance, with an average of 2.5
kPa. This is similar to what was previously observed when
expressing utrophin from the strong cytomegalovirus
(CMV) promoter [29]. We concluded that the inducible
system allowed the functional recovery of the muscle fiber
sarcolemmal membrane, and that the network expression
system may therefore confer sufficient utrophin expres-
sion to mediate a therapeutic effect.
MAR elements mediate sustained transgene expression in
muscle in vivo
Epigenetic regulatory DNA sequences termed MAR
were previously linked to a wide diversity of processes,including the attachment of chromatin to the nuclear
matrix, chromatin remodeling, and stabilization of trans-
gene expression [10,30]. They have been shown to medi-
ate expression from episomal replicating vectors when
transcribed, however they were also associated to an in-
creased genomic integration of transgenes when incor-
porated into plasmid expression vectors upstream of the
promoter [31,32]. We previously identified two potent
human MAR (hMAR) elements from chromosome 1
and X, termed MAR 1–68 and X-29 respectively, that
each could sustain GFP expression in cultured cells, in-
cluding muscle stem cells, and in mouse muscles after
transplantation and differentiation [9, Van Zwieten et al.,
submitted for publication]. Also, these MARs mediated
elevated levels of circulating red blood cells upon the ex-
pression of a secreted protein, erythropoietin (EPO) [10].
However, the mode of action of these MARs and the
duration and levels of transgene expression after in vivo
electrotransfer have not been characterized.
To assay the effect of MAR 1–68 and X-29 in mouse
muscles, constitutive GFP expression vectors contain-
ing or not the MAR upstream of the promoter were
electrotransferred into the muscles of C57Bl/6 mice as
before. This revealed an average of approximately 50%
of GFP-positive fibers 7 days after the electrotransfer,
irrespective of the inclusion or not of a MAR (Figure 3A).
However at day 56 post-electrotransfer, only muscles
injected with the vectors containing the human MAR
(hMAR) 1–68 and hMAR X-29 showed sustained and
higher GFP expression levels. When the average GFP
fluorescence levels were quantified in the myofibers of
whole muscle sections, we found that the expression levels
had even increased with hMAR 1–68, which is reminis-
cent of the ability of this MAR to reverse transgene silen-
cing in cultured cell lines [33]. Two other MAR elements
of human or murine origin evaluated in parallel did not
confer similarly elevated and fully sustained long-term ex-
pression (data not shown). The hMAR 1–68 was therefore
selected for inclusion into the final versions of the network
plasmids, upstream of the regulated promoters that drive
the expression of the activator and therapeutic genes in
the 5XGal4-7XtetO-Gal4VV and 5XGal4-7XtetO con-
structs, respectively, in the following experiments.
hMAR 1–68 mediates persistent expression
We next assessed the kinetics of transgene expression by
probing circulating levels of the secreted murine EPO
protein when expressed from the regulatory network.
Maximal induction of EPO levels in the blood plasma of
electrotransferred mice was obtained after 5 days of
doxycycline treatment in the absence of the MAR.
Thereafter, expression decreased rapidly, with EPO levels
dropping to levels such as those of non-induced mice
after 15 days (Figure 4A, and data not shown). When
Figure 2 Regulated utrophin expression in in vivo electroporated mouse muscles. Mouse muscles were electroporated with the optimized
version of Network system, consisting of the pCAG-htetR-TR450W repressor, 5Xgal4-7XtetO-Gal4VV activator and 5Xgal4-7XtetO-mUtrophin
reporter constructs. The therapeutic efficacy of regulated utrophin expression in the muscles of mdx mice was assessed by atomic force microscopy
[AFM, as described by Puttini et al. (2009)]. AFM assays of muscles from wild type (WT) or dystrophic (mdx) mice were performed as controls (A, B).
Alternatively, 8 weeks mdx mouse muscles were assayed two weeks after the electrotransfer of the regulatory network containing the utrophin cDNA
as a therapeutic transgene, and with the addition or not of doxycycline in the mice drinking water, as indicated (C, D). Muscle explant sections were
immobilized and thereafter assayed using the AFM pressing mode to determine the force required to reach a given indentation in individual muscle
fibers, as an assay of the expression of sufficient levels of functional utrophin to restore a normal resistance to the muscle fibers sarcolemmal
membrane [29]. Results of several hundreds of independent measurements performed on distinct section locations and myofibers are represented as
the distribution of Young’s modulus values in histograms constructed with a bin size of 0.5 kPa, which quantitatively describe the muscle’s resistance
to mechanical deformation. Here, we pooled the results from 4 independent experiments, each one consisting of 2 electroporated animals, one treated
with dox and the other one left untreated. Each animal had an 1 electrotransfer in each of the two tibialis muscles, and each muscle was processed
into at least 2 sections, so a minimum of 4 muscle sections were measured per condition and experiment.
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moters driving the expression of the activator and of the
EPO gene, sustained expression was obtained in the
presence of doxycycline, while expression levels in the
off-state were not perturbed by inclusion of the hMAR
(Figure 4B).
As expression levels from the constitutive CAG pro-
moter driven repressor construct were sufficient for
sustained inhibition of the regulated promoters in the
OFF-state in vivo, inclusion of a MAR in this plasmid
vector was deemed unnecessary for the efficiency of the
hTetR-TR450W-based network system. This is consist-
ent with our previous observations that constitutive ex-
pression from another strong promoter was not prone
to loss-of-expression effects in electrotransferred mice
muscles [10].
We hypothesized that the long-term expression ob-
served from the regulated promoters in the presence of
the MAR might either result from a protection against si-
lencing effects, or from the abrogation of plasmid loss.This was assessed by quantifying the number of episomal
plasmid copies remaining in the mouse muscles after the
electrotransfer of GFP-expression plasmids. Total DNA
was extracted from electrotransferred mouse muscles, and
a “plasmid rescue” experiment was performed. This con-
sisted of transforming electro-competent bacterial cells
with aliquots of the total DNA extracts, followed by quan-
tification of ampicillin-resistant colonies after plating. One
day after electrotransfer of the MAR-devoid plasmids,
the number of ampicillin-resistant colonies was 30-fold
higher than after 5 days, irrespective of the inclusion of
a MAR element (Figure 4C and data not shown). We
therefore concluded that most injected plasmids were
quickly lost, as expected from the previously reported
fast lymphatic draining of plasmids remaining in the
interstitial space surrounding muscle fibers [19]. There-
after, the number of colonies obtained from MAR-
devoid constructs remained stable for over 3 months,
indicating that the remaining plasmids were stably
maintained as episomal structures in the muscle.
Figure 3 Expression of MAR-driven GFP genes after mouse muscle electrotransfer. Wild-type mice muscles were injected with 30 μg of
GFP expression plasmids containing or not a MAR element, or injected with saline for control muscles, as indicated, prior to electrotransfer.
Muscles were collected 7 or 56 days after the electrotransfer. Representative transversal muscle sections illustrate the background and GFP
fluorescence in green and the extracellular matrix proteins with Wheat Germ Agglutinin separating individual myofibers in red colors (A).
The GFP fluorescence of single myofibers was quantified in 4 muscle sections from 2 mice per condition, and they are represented as the
average and standard deviation of the GFP fluorescence of individual myofibers, after the subtraction of the background fluorescence values
determined from the control muscles (B).
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were tested in the plasmid rescue assay, episomal structures
were quickly lost, being lower 5 days post-electrotransfer
and becoming undetectable after 25 days (Figure 4C), des-
pite the persistent muscular transgene expression levels.
When plasmids were mixed to total genomic DNA ex-
tracted from non-electrotransferred muscles followed by
bacterial transformation, similar bacterial colony counts
were obtained with plasmids containing or not the hMAR
(Additional file 2). This indicated that the mere presence of
the MAR or plasmid size differences could not explain the
total loss of detectable episomal MAR-containing plasmids
25 days after in vivo electroporation. As the expression
plasmid DNA must still be present, since stable and high
EPO levels are still being expressed (Figure 4B), we rea-
soned that the MAR-containing plasmids might become
entangled in some cellular structure or may form large
concatemers, such that they would not be recovered in
muscle extracts and/or not transform in bacteria because
of their large size. Alternatively, the hMAR might havepromoted plasmid integration into the genome of muscle
fibers, converting the episomal transgenes into chromo-
somally integrated structures.
Persistence of hMAR 1-68-containing plasmids in murine
muscles
MAR elements have been implicated with an activation of
homologous recombination and with the formation of
plasmid concatemers in transfected cell lines [31]. Persist-
ence of the electrotransferred DNA was assessed by evalu-
ating the total number of copies of GFP transgene in
mouse muscle extracts by quantitative PCR (qPCR), as well
as the fraction of it remaining in circular structures. The
total transgene copy number was comparable throughout
a time course, when comparing constructs containing or
not a MAR after muscle electrotransfer (Figure 5A). When
the GFP transgene copy number was normalized to that
of the chromosomal GAPDH gene, high transgene copies
per diploid genome were found at day 1, followed by a
stable but much lower occurrence of transgene copies per
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assay (Figure 5A and data not shown). We concluded from
these findings that the loss of recoverable MAR-containing
plasmids cannot be attributed to a preferential loss of
the vector DNA or from the disappearance of MAR-
containing muscle fibers, but that it may relate to the epi-
somal status of the various vectors.
Thus, we next assessed whether the disappearance of re-
coverable episomal plasmids in presence of the MARG
FP
 
tra
ns
ge
ne
 c
op
ie
s 
'22
2#G
FP
 
tra
ns
ge
ne
 c
o
pi
es
  
(co
pie
s p
er 
ge
no
me
) 
A B 
Figure 5 Total and episomal transgene DNA quantification. (A) Real-ti
electrotransfer. GFP expression vector containing the indicated MAR eleme
day after the electrotransfer, total DNA extracts were prepared from the m
numbers were normalised to those of the cellular GAPDH gene, and they a
myofiber nuclei. (B) Muscles of mice were collected 1 or 5 day after the ele
element, as indicated. Total DNA was extracted and processed to quantify
GFP DNA). Alternatively, the DNA preparations were treated with the PS-DNas
integrated linear DNA molecules (Episomal GFP DNA). GFP DNA amounts wer
are expressed as the average number of copies per diploid myofiber nucleus,
injected muscles.might result from the chromosomal integration of the vec-
tors. To do so, we treated all DNA extract samples with
PS-DNase (Plasmid-safe DNase), a strict exonuclease that
allows the digestion of all linear chromosomal DNA, but
that does not digest episomal circular DNA structures, as
demonstrated for instance for adenovirus-associated viral
genomes and derived vectors extracted from mouse, pri-
mate and human muscles [34-36]. Selectivity of the nucle-
ase was ascertained in control studies performed on total(co
pie
s p
er 
ge
no
me
) 
Total GFP DNA 
Episomal GFP DNA 
me PCR quantification of total GFP transgenes after muscle
nt were introduced in mice muscles by electrotransfer. At the indicated
uscles. 120 ng of total DNA was used for qPCR assays. GFP copy
re represented as the average number of GFP gene copies per diploid
ctrotransfer of GFP-expression plasmids containing or not a MAR
the GFP transgene and GAPDH cellular gene by quantitative PCR (total
e exonuclease to degrade all transgenes occurring as chromosomally
e normalized to those of GAPDH prior to PS-DNase treatment, and they
after substraction of the background non-specific values obtained for not
Puttini et al. BMC Molecular Biology 2013, 14:26 Page 8 of 12
http://www.biomedcentral.com/1471-2199/14/26genomic DNA spiked with circular or linear plasmids, as
well as on chromosomally-integrated GFP expression vec-
tors. This indicated that 99% or more of the linear DNAs
were digested by the PS-DNase, while more than 90% of
the circular plasmids were not (Additional file 3).
One day after electrotransfer, digestion with the PS-
DNase indicated the occurrence of an average of approxi-
mately 10 copies per genome of circular plasmids when
devoid of a MAR, while this was decreased to 2 copies
in presence of hMAR 1–68 (Figure 5B). As a similar num-
ber of total GFP gene copies was obtained when the
chromosomal DNA was not digested with the PS-DNase,
we concluded that the hMAR 1-68-containing plasmid
had integrated into cellular chromosomes with a higher
frequency. 5 days after the electrotransfer, the amount
of MAR-containing episomal vectors dropped to levels
close to the detection limits, implying that most if not all
plasmids had integrated in the genome (Figure 5B and
Additional file 3). Although some of the MAR-devoid
plasmids remained in episomal form, a proportion of it ap-
peared to have integrated chromosomally as well. Interest-
ingly, hMAR X-29 appeared to mediate a slower rate of
plasmid integration as compared to hMAR 1–68, as it was
indistinguishable from the MAR-devoid plasmid at day 1,
while it was essentially completely integrated at day 5.
Overall, this indicated that MAR-devoid plasmids
can persist as episomes after muscle electrotransfer,
while MAR-containing constructs remain at compar-
able copy number, but in a form that may be chromosom-
ally integrated. Interestingly, both types of vectors were
retained at a comparable number of copies in the long
term, stabilizing around 1–10 copies per genome on
average (Figure 5A), but expression persisted only for
the MAR-containing plasmids.
Discussion
In this study, we wished to optimize and document sets
of vectors for regulated in vivo expression that rely on
an activator and a repressor protein functioning in a net-
work regulated by doxycycline, a tetracycline antibiotic
derivative commonly used to treat infections in humans.
We found that a wide regulatory window can be ob-
tained from this network once constituents of the regu-
latory system were adapted and optimized for in vivo
use. Notably, we used a humanized TetR, optimized the
repressor strength and used a constitutive cellular pro-
moter that showed no detectable epigenetic silencing.
We also demonstrated that this regulated gene expres-
sion system can be used to express therapeutic trans-
genes in vivo at levels reaching physiological relevance
for the utrophin myofiber protein and for the murine
EPO circulating hormone.
We also found that induced expression was quite
short-lived in the regulated hTetR-TR450W networkwhen circulating EPO levels were quantified from blood
drawn from the same mice at distinct times after elec-
trotransfer. This loss-of-expression effect could be coun-
teracted by the inclusion of a MAR element next to the
regulated promoters, allowing persistent EPO expression
in inducing conditions, and yet without altering the tight
repression observed without doxycycline. We also found
that inclusion of MAR elements in the plasmids not only
allowed persistent expression, but that this was accom-
panied by the rapid loss of episomal vector and by the
likely chromosomal integration of the electrotransferred
plamids. Similar observations were made using vectors
mediating either regulated or constitutive expression,
when expressing various types of recombinant proteins
of either heterologous (GFP) or autologous (EPO) origin,
when using several distinct MAR elements, and when
assessing the fate of the transferred plasmids by unre-
lated assays (the rescue of episomal plasmids or the deg-
radation of the chromosomal DNA).
Early studies exploring the fate of plasmids after muscle
electrotransfer obtained no evidence of chromosomal inte-
gration of plasmids [37]. However, later and more sensitive
assays indicated that plasmids do integrate upon electro-
transfer, although a significant proportion of the plasmid
vector can remain extra-chromosomal [38]. Here we find
that chromosomal integration may be significantly in-
creased upon addition of MAR elements in plasmid vec-
tors, and that only trace amounts of the plasmids may
remain in circular episomal form when containing the
hMAR 1–68. These results are reminiscent of recent
observations that hMAR 1–68 can promote and signifi-
cantly increase the integration of plasmids in the chromo-
somes of cultured CHO cells during stable transfections
[31]. Here, we find that this MAR may have a similar
integration-promoting activity in muscle fibers in vivo,
and that it may be more potent in this respect when
compared to other human MARs such as hMAR X-29.
Grandjean et al. (2011) showed that MARs promote plas-
mid integration by a homologous recombination-related
mechanism, while Wang et al. (2004) showed that electro-
transferred plasmids often integrate at AT-rich chromo-
somal loci. As the MAR elements such as those used in
this study are prominently AT-rich, it will be interesting to
determine if plasmid-borne MARs may promote plasmid
integration at genomic loci containing homologous cellu-
lar MAR elements. Whether plasmids containing a MAR,
as electrotransferred in our assays, have a tropism for in-
tragenic regions remains unknown, as our sequencing ef-
forts directed at identifying transgene integration sites
with a MAR were unsuccessful. Thus, a potential geno-
toxicity of genome-integrated MAR-containing plasmids
cannot be excluded at present. Nevertheless, the hTetR-
TR450W based network inducible system was evaluated
at several time points and up to 9 months, during which
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was noticed in all tested conditions for over 100 mice
altogether.
In this study, we have devised a novel method to assess
more quantitatively the fate of plasmids upon electrotrans-
fer, as based on the use of a strict exonuclease coupled to
real time quantitative PCR assays. Results obtained with
this approach suggested that plasmid integration may be
more frequent than previously considered. For instance,
Wang et al. (2004) reported that integration events remain
infrequent, and that this may only concern a small percent-
age of total plasmid DNA, at least for MAR-devoid plas-
mids. In contrast, our results suggest that a significant
proportion of the plasmids might integrate, even without a
MAR element. Conceivably, the occurrence of circular plas-
mids may be underestimated by the damaging of circular
plasmids upon extraction, which would result in their deg-
radation by the exonuclease. Although this cannot be for-
mally ruled out, control spiking experiments indicated that
degradation of plasmids by the DNase should not exceed
10-20% of the circular molecules. In any case, the integra-
tion of electrotransferred DNA upon in vivo electrotransfer
has now been reported in several independent studies, and
this should be taken in consideration when studying poten-
tial therapeutic use of DNA electrotransfer for humans.
We find that the total amounts of transgenes persisting
25 days post electrotransfer or later are similar when com-
paring plasmids that contain or not a MAR element. How-
ever, transgene expression persists in the presence of the
MAR, while it is gradually silenced in absence of this
element. This is unlikely to result from the organization of
the regulatory network, as we also observed this effect for
constitutive GFP expression in electrotransferred muscles.
Previous observations have indicated that the presence of
prokaryotic DNA sequences, such as the bacterial anti-
biotic selection gene, may lead to the formation of hetero-
chromatin and to silencing effects [39]. Consistently, use
of plasmid vectors deleted of sequences of bacterial origin,
termed minicircles, have been associated with more per-
sistent expression [40]. Our findings illustrate that inclu-
sion of a MAR may also oppose such silencing effects,
obviating the need to remove vector sequences. This inter-
pretation is supported by the previous finding that hMAR
1–68 sustains transgene silencing after chromosomal inte-
gration, and that it can even act to reverse established
silencing effects in cultured cell lines [33]. Here, we ob-
served increasing GFP expression at later times after the
electrotransfer of MAR-containing plasmids, suggesting
that the MAR elements can promote expression from si-
lent transgenes in vivo as well as in vitro.
Conclusions
Taken together, our findings indicate that MAR elements
may be used to mediate persistent and more reliableregulated or constitutive expression in differentiated tis-
sues in vivo, although this may imply an increased fre-
quency of genomic integration of the transgenes.
Methods
Ethics statement
This study was carried out in strict accordance with the
Swiss guidelines for the care and cure of animals (i.e. the
Federal law on the protection of animals, and the Ordin-
ance on the protection of animals). The protocol was
approved by the Animal Experimentation Committee
of the Veterinary Service of Canton de Vaud (Permit
Number: VD1962). All blood sampling was performed
under isoflurane anesthesia, and all efforts were made to
minimize suffering.
Plasmids constructs
All plasmids were generated using standard techniques
and verified by sequencing. The pTet-ON™ and pTet-
Off™ plasmids were obtained from Clontech. The TetR
coding region of pTet-Off™ was fused to the SV40 large
T antigen nuclear localisation signal (NLS) and to vari-
ous transcriptional repression domains, as described
previously [9]. The coding sequences for the fusions re-
pressors were inserted in the pCAGGS expression vector
under the control of chicken β actin CAG promoter
(kindly provided by Jun-ichi Miyazaki, University of Tokio;
[41]). Reporter plasmids were previously described [6].
The vector used to express the transcriptional activator
Gal4VV was generated from pGAL-VP16 [6] by replacing
the full length VP16 activation domain by a dimer of its
minimal acidic activation domain [42]. The humanised
version of TetR (hTetR) was kindly provided by W. Reith
[24]. The final combination of elements of the network vec-
tors were termed CAG-hTetR-TR450W for the repressor,
5XGal4-7XtetO-Gal4VV for the activator, and 5XGal4-
7XtetO for the reporter or therapeutic constructs.
Plasmids containing the utrophin, erythropoietin or
the luciferase cDNA subcloned under the control of the
5Xgal4-7XtetO inducible promoter of the network sys-
tem where used where indicated. The human MAR 1–
68 was cloned upstream of the inducible promoter in
the network activator and reporter constructs where in-
dicated. MAR 1–68, or another human MAR, MAR X-
29, were placed upstream of the SV40 promoter driving
eGFP constitutive expression, for comparison to the par-
ental MAR-devoid construct.
DNA purification for electrotransfer
Pellets of overnight 1 liter bacterial cultures were resus-
pended in Glucose/Tris/EDTA (GET) and freshly pre-
pared 0.2 M NaOH/1% SDS solution was added for
alkaline lysis. Neutralization was done with 3 M potas-
sium acetate solution (pH 5.5) and DNA was then
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was resuspended in TE buffer, and 1 g of CsCl per ml of
solution was added. The solution was transferred to a
12 ml ultracentrifuge tube, to which ethidium bromide
was added before sealing 100 μl of 10 mg/ml Tubes were
centrifuged in a Beckman ultracentrifuge with a Vti90
rotor at 79000 rpm for 13.5 hours. The supercoiled plas-
mid DNA band was collected and the ultracentrifugation
was repeated. After DNA band collection, ethidium
bromide was removed by extraction with an equal vol-
ume of NaCl-saturated isopropanol. Plasmid DNA was
dialyzed against 150 mM NaCl.
Intramuscular electrotransfer of genes and doxycycline
administration
In vivo experiments were carried out on 5–6 week-old
C57BL6 female mice (Iffa Credo-Charles River, France) or
mdx5cv (in-house animal facility). Animals were housed
in a facility with food and water ad libitum.
The tibialis anterior muscles were pre-treated with
hyaluronidase 2–4 h before plasmid injection using a
Hamilton syringe. The muscles were injected with 0.8
U/μl of bovine hyaluronidase in 25 μl of normal saline
[28]. Plasmid DNA (1 μg/μl) in normal saline was injected
intramuscularly. All injections (30 μl) were carried out in-
side the tibialis anterior muscle, under Ketaminol
(100 mg/kg) and Narcoxyl (10 mg/kg) sedation. Following
the intramuscular injection of DNA, an electrical field was
applied to the muscle. The electrodes were applied to the
medial and lateral sides of the lower hind limb and elec-
trode jelly was used on the electrode to ensure good elec-
trical contact. A voltage of 200 V/cm was applied in 8 ms
pulses at 1Hz with a BTX electroporator. Doxycycline-
HCl (SIGMA) was dissolved in drinking water at final
concentration of 400 μg/ml, 3% (wt/vol) sucrose and 4%
ethanol, which was provided ad libitum to the mice. The
proportions of repressor, activator and reporter constructs
were 0.05 μg, 15 μg and 15 μg respectively in the final ver-
sion of the hTetR-TR450W-based network system. No
deleterious effect of plasmid injection or of the electro-
transfer process was observed, as observed from the oc-
currence of centrally located nuclei with muscle sections
(Additional file 4).
Luciferase, renilla and EPO assays
After sacrifice of the mice by cervical dislocation, mus-
cles were collected two weeks after the electrotransfer
and resuspended in 2 ml of Passive lysis buffer (PRO-
MEGA) with the addition of the Protease Inhibitor
Cocktail tablets (Roche) and homogenized by Ultra-
thurax (Heidolph). Samples were centrifuged for 10 min
at 12,000 rpm, and 10 μl supernatants were tested in du-
plicates for luciferase and renilla activity using the Dual-
Luciferase® Reporter Assay System (PROMEGA).Blood samples were collected by retro-orbital puncture
of mice anesthetized with 5% Isofluorane. The separated
plasma was used for murine EPO determination by the
Quantikine enzyme linked immunosorbent assay (R&D
Systems).
AFM and histological assays
The processing of tibialis anterior muscles in thick lon-
gitudinal sections and AFM assays were as described
previously [29]. We used Mann–Whitney test to compare
the distributions and they were scored as statistically sig-
nificantly different with p < 0.05. For GFP quantification,
tibialis anterior muscles were transversally sectioned at
10 μm thickness and incubated 1 hour with Alexa Fluor
594-labelled Wheat Germ Agglutinin (2 μg/ml) in PBS
(Molecular Probes w-11262), to stain the extracellular
matrix glycoproteins. After 3 washes in PBS, slides were
mounted with VECTASHIELD® Mounting Medium. The
fluorescence of the Green Fluorescent Protein was directly
assessed by fluorescence microscopy in the sarcoplasma of
muscle fibers and was quantified using the Tissue Quest
image analysis software (Tissue Gnostics, Vienna, Austria).
Between 2000 and 3000 fibers per slides were analyzed
and the mean fluorescence was recorded.
Purification of total DNA from muscles and quantification
of episomal plasmids
Total DNA was purified from murine muscle explants
using the Blood & Cell Culture DNA Mini Kit (Qiagen)
following the manufacturer’s instructions. Elution of the
extracted total DNA was performed in 200 μl of water.
Transformation was performed with 1 μl of the total
DNA solution added to 25 μl of ultra electro-competent
cells DH-10B (Invitrogen). After a 2 kV electrical pulse,
bacterial cells were incubated in LB for 1 h at 37°C and
plated on ampicilline-containing LB AGAR plates.
DNA quantitative PCR assays
Qantitative PCR was performed in 15 μl containing
175 ng of total genomic DNA extracted from eletrotrans-
ferred mice muscles, or as otherwise indicated in the fig-
ure legends. 40 cycles of amplification were performed
using GFP (AGCAAAGACCCCAACGAGAA and GGCG
GGGGTCACGAA) oligonucleotides as primers, and the
mouse GAPDH primers (CGACCCCTTCATTGACCTC
and CTCCACGACATACTCAGCACC) as a reference.
Plasmid Safe DNase treatment and qPCR
2.5 μg of total mouse muscle genomic DNA was
digested with 100 U Plasmid safe DNase, 5 μl of ATP
(100 mM) in 500 μl for 8 hours at 37°C. This was
followed by the addition of an additional 100 U of Plas-
mid Safe DNase and 5 μl of ATP (100 mM), followed by
an over-night incubation. When processing the genomic
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50% of the extract was diluted to 500 μl, and two add-
itional cycles of treatment with 100 U of Plasmid Safe
DNase were performed as before, to ensure the total
degradation of the chromosomal or damaged plasmid
DNA. 7 μl of the digestion mix (containg 30 ng of total
DNA) was processed to quantify the GFP and GAPDH
undigested DNAs in 15 μl qPCR reactions. The copy
number of the GFP transgene was normalized to the
copy number of the GAPDH chromosomal gene prior to
treatment with the DNase, taking in consideration the
average efficiency values of the GFP and GAPDH ampli-
fication reactions as described previously [43]. Because
we observed that inclusion of the PS-DNAse buffer low-
ered the qPCR-mendiated quantification of the GAPDH
reference gene, a correction factor of 0.1 was applied to
data from qPCR reactions that contained the PS-DNase
mix, so as to reflect the true DNA quantities as deter-
mined in control titration reactions with or without the
PS-DNase mix (Figure 5B).Additional files
Additional file 1: Dose–response titration of the EF-1α-hTETR-
TR450W repressor vector. Constant amounts (10 μg) of the activator
(5XGTTIGal-VV) and reporter gene (5XGTTI-luc) expression plasmids were
introduced into mouse tibialis anterior muscles together with a renilla
reference plasmid and varying amounts of the repressor protein
expression vector (EF-1a-hTETR-TR450W), as indicated. Analysis of the
expression levels was performed 10 days after the electrotransfer, from
muscle extracts obtained from mice provided of not with doxycycline in
the drinking water.
Additional file 2: Plasmid transformation efficiency. The
transformation efficiency of GFP expressing vectors containing or not the
indicated MAR element, as used in Figures 3 and 4C, was compared to
that of the smaller parental pUC plasmid. 10 ng of plasmids were mixed
with 100 ng of total genomic DNA extracted from muscles not subjected
to an electrotransfer, and the mixes were added to electrocompetent
bacterial cells for transformation by episomal plasmids as described in
the Methods. The star sign indicates statistical significance (p < 0.05)
while ns stands for non-significant.
Additional file 3: Real-time PCR quantification of genome-
integrated, linear or circular episomal GFP DNA. Total genomic DNA
was extracted from either non-injected mouse tibialis anterior muscles, or
from primary murine mesioangioblast muscle-precursor cells having
stably integrated approximately 4 copies of the GFP coding sequence
into one of their chromosomes. 10 ng of genomic DNA were mixed or
not with 4 pg of supercoiled circular or linearized GFP expression
plasmid, as indicated, which corresponds to approximately 430 copies of
the 4.3 kb GFP-coding plasmid per diploid genome. The mix was
incubated twice with 100 units of the Plasmid Safe (PS) DNAse during
12 h, in two consecutive incubations, to assess the plasmid resistance to
degradation. Alternatively, the genomic DNA was similarly incubated
twice for 12 h with the PS-DNAse, and the circular plasmid was added at
the end of the incubations just before DNA purification and quantification
of the GFP sequence by qPCR. The GFP gene copy number was normalized
relative to that of the genomic GAPDH gene (prior to digestion), and it is
represented as the GFP sequence copy number per diploid genome,
assuming a total number of 660 GAPDH gene and pseudogene copies per
diploid genome (Liu et al., 2009). Values lower than 0.1 GFP copies per
genome indicate background noise values, as obtained with the genomic
DNA devoid of GFP sequence as in the first two lanes. Over 90% of thesupercoiled plasmids incubated with the DNAse remained undigested,
whereas linearized plasmids or chromosomally-integrated GFP transgenes
are digested to near near completion (99%) by the PS-DNAse.
Additional file 4: Quantification of central nuclei in WT and mdx
muscle fibers following electrotransfer. We quantified the number of
central nuclei (representing regenerating muscle) in WT and mdx mice,
electrotransferred or not with DNA, 7 days after the experiment. Cryostat
muscle sections were stained by hematoxyline/eosine method, and the
location of nuclei was quantified by microscopy. No significant effect of
electroporation or of the DNA was detected from 3 different muscle
sections for each condition.
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